Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.59 |
| ▸ | ITGAV | P06756 | 10/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869337 | 0.91 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7216172 | 0.89 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7216180 | 0.89 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6869118 | 0.88 | ITGB3 (0.59) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6861751 | 0.87 | ITGB3 (0.52) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6870984 | 0.83 | ITGB3 (0.60) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6866425 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6861629 | 0.83 | ITGB3 (0.57) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6871462 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL14547079 | 0.82 | ITGB3 (0.71) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155003-B1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-6340679-B1 | FOR INHIBITING BONE RESORPTION, OSTEOPOROSIS, TUMOR GROWTH OR TUMOR METASTASIS, INFLAMMATION, OR FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS, RESTENOSIS, ARTERIOSCLEROSIS, NEPHROPATHIES, RETINOPATHIES OR RHEUMATOID ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-22 | — | — | US | disclosed |
| EP-1155003-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047564-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-17 | — | — | WO | disclosed |
| EP-1028114-A1 | Novel guanidine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2000-08-16 | — | — | EP | disclosed |